PDB50 MYTHS AND REALITIES OF TREATMENT SATISFACTION IN DIABETES  by Brod, M et al.
A239Abstracts
(in duplicate 15-days separated to assess test-retest reliability),
trait-anxiety scale of the STAI and eight speciﬁc questions about
glycemic control, compliance and pain were administered.
Sociodemographic and clinical data were also collected. Feasi-
bility (item and questionnaire responder rate and time to com-
pletion) content validity (item-total correlation and factor
analysis), concept validity (correlation with STAI and speciﬁc
questions) and reliability (test-retest and Cronbach’s Alpha) were
assessed. RESULTS: A 32-items version was developed by an
expert panel and administered to 93 (35 Type 1, 58 Type 2)
insulin-treated diabetic patients. Ninety-nine% of patients
answered all items in 5 minutes (median). Item-total correlation
and factor analysis lead to an abridged version with 19 items,
maintaining the two original dimensions, and explaining the
47.4% of total variance: FSI; 29.5%, and FST;17.9%. Test-retest
correlation coefﬁcient were 0.85 (FSI) and 0.94 (FST); Cron-
bachxs Alpha were 0.81 (FSI) and 0.89 (FST). FST correlated
positively with time treated with insulin (p < 0.011, type 2); FSI
correlated positively with patient reported compliance (p =
0.002) and lack of worry in diabetes consequences (p = 0.005,
type 2), and negatively with time treated with insulin (p < 0.023,
type 1). CONCLUSIONS: We developed a new-recalibrated
version of the Spanish D-FISQ called MIAT-D. Feasibility,
dimensionality, content validity and reliability were accurate.
Due to the fact of cultural differences and lack of a gold stan-
dard for concept validity, this property need to be explored in
further studies.
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OBJECTIVES: Management of Spanish patients with Type 2 
diabetes and predictors of adherence to their medication.
METHODS: Multicenter, naturalistic study of type 2 diabetes
patients with a diagnosis longer than one year. Patients were con-
secutively included in the study among those attending any of
the selected 30 Primary Care Centers distributed throughout
Spain Sociodemographic and clinical variables were collected.
Patients completed the Morisky-Green questionnaire as a
measure of adherence. A logistic regression was performed with
sociodemographic, clinical, and treatment variables to predict
factors of adherence. RESULTS: A total of 294 patients were
included in the study (mean age = 67.5 yrs; mean duration of dia-
betes = 9. 9yrs). A total of 6.1% were not receiving anti-diabetic
pharmacological treatment, 70.4% received oral(s) therapy,
10.9% were in insulin therapy, and 12.6% a combination of
insulin and oral(s) therapy. A total of 58.2% of patients had poor
glycemic control (HbA1c > 6.5%). With respect to diabetic com-
plications, 20.4% of patients suffered from microvascular com-
plications only, 11.2% reported macrovascular issues only, while
14.3% suffered from both micro and macrovascular complica-
tions. The Morisky-Green questionnaire showed only 47.8% of
patients under pharmacological treatment reported a high level
of adherence. The logistic regression models showed in that in
those patients receiving only insulin, the probability of having a
high level of adherence is signiﬁcantly higher (odds ratio : 2.7)
than non-insulin receiving patients. Moreover, when a patient’s
HbA1c value is lower by one percentage point, the probability
of having a high level of adherence is greater (odds ratio : 1.3)
compared to the adherence seen at a higher A1c level. CON-
CLUSIONS: Oral agents were the most commonly prescribed
anti-diabetic pharmacological agent. Less than half of the
patients reported high adherence to their medication. The level
of diabetes control and insulin treatment were found to be asso-
ciated with adherence although further work should investigate
the causal relationship between these variables.
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OBJECTIVES: Patient reported outcomes (PRO), quality of life
(QoL) and clinical efﬁcacy achieved with a combination of
insulin glargine (GLA) and insulin glulisine (GLU) were docu-
mented in daily practice. METHODS: An observational study in
Germany documented 1447 type 1 patients (age 42.6 ± 14.5
years) and 5695 type 2 patients (age 61.8 ± 10.5 years) insufﬁ-
ciently controlled under prior intensiﬁed insulin therapy who
were switched to GLA (mean daily dose at baseline 21.8 ± 9.6
I.U. for type 1 and 24.4 ± 13.0 I.U. for type 2) and GLU (28.0
± 13.0 and 34.4 ± 23.0 I.U. respectively) for 89 and 91 days in
median respectively. Efﬁcacy was measured by fasting blood
glucose (FBG) and HbA1c values. QoL was evaluated with a 5-
item-Likert-scales from physician`s perspective. PRO was mea-
sured with a visual analogue scale (VAS) and a diabetes treatment
satisfaction questionnaire (DTSQs) respectively. RESULTS: The
ﬁndings are given for type 1 and type 2 respectively. Mean FBG
levels decreased about 36.4 ± 48.7 and 48.3 ± 41.6 mg/dl,
HbA1c-values about 1.0 ± 1.2 and 1.2 ± 1.0% compared to pre-
vious therapy. Sum scores for six categories of QoL in physician’s
assessment improved from 14.5 ± 3.6 to 10.1 ± 3.1 at follow-up
and from 15.4 ± 3.7 to 10.4 ± 3.2. VAS-scores (0 to 100 scale)
improved from 41.9 ± 22.0 to 19.6 ± 14.1 and from 49.6 ± 20.9
to 22.8 ± 16.0, DTSQs-sum scores from 20.7 ± 6.7 to 29.3 ± 5.1
and from 19.1 ± 6.6 to 28.4 ± 5.4 (p < 0.0001 for all reduc-
tions). CONCLUSION: In comparison to preceding insulin
treatment, basal-bolus therapy with GLA and GLU improved
various treatment satisfaction measures from different perspec-
tives in accordance with clinical efﬁcacy.
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OBJECTIVES: Clinical wisdom assumes that treatment satisfac-
tion (TS)with insulin improves with fewer injections and side
effects. We examined the relationships between TS, patient char-
acteristics (age, gender, ethnicity, weight, co-morbidities, diabetes
duration) and treatment outcomes (HbA1c, number of daily
injections, weight gain, hypoglycemic events).METHODS: Base-
line and 28 week RCT data comparing efﬁcacy and safety of
Biphasic Insulin Aspart 70/30 (BIAsp 70/30, NovoMix®
30/NovologMix® 70/30) vs. insulin glargine in type 2 diabet-
ics(n = 240) were analyzed. Subjects completed the Insulin Treat-
ment Satisfaction Questionnaire (ITSQ—overall TS and 5
domains: Lifestyle Flexibility, Hypoglycemic Control, Glycemic
Control, Device Satisfaction, Inconvenience of Regimen).
Regression analyses examined the relationship between TS,
patient/disease characteristic and outcomes. Signiﬁcant factors
were examined together by multivariate regression analyses.
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RESULTS: The presence of diabetes-related co-morbidities,
notably neuropathy predicted overall TS and 3/5 domains (p <
0.05). Retinopathy impacted Device Satisfaction, age was related
to Lifestyle Flexibility (p < 0.05). No other baseline patient/
disease characteristic impacted TS. Lowered HbA1c impacted
overall TS, and 3/5 domains (p < 0.05). Number of hypoglycemic
events impacted Hypoglycemic Control, timing of the event was
related to overall TS and all domains (p < 0.001). Weight gain,
number of daily injections and treatment group did not impact
TS despite the presence of signiﬁcant treatment group difference.
When all signiﬁcant factors were examined together, HbA1c
reduction and neuropathy maintained their impacts on TS. The
impact of the number of hypoglycemic events remained only for
Hypoglycemic Control, while timing of the hypoglycemic event
impacted overall TS and 3/5 domains (p < 0.01). CONCLU-
SION: Contrary to clinical wisdom, the number of daily injec-
tions may not negatively impact TS when balanced by signiﬁcant
HbA1c treatment beneﬁts. Factors impacting TS when examined
independently did not always exert the same signiﬁcant inﬂuence
when assessed in combination with other factors. Clinicians
should judge the balance between positive and negative treat-
ment outcomes before considering treatment options.
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OBJECTIVES: The prevalence of thyroid nodules is high with
four to seven percent in the general population. Fine-needle aspi-
ration cytology (FNA-t) is recommended as the reference test
because it is minimally invasive, presents an optimal positive pre-
dictive value and is cost-effective when compared to whole-body-
scan (WBS). The diagnosis is known for the fraction of patients
operated. Suspicious ﬁndings are a dilemma. For benign and
indeterminate results, a long-term follow-up delayed the time of
diagnosis. This study aims to determine the total cost of a true
diagnosis by FNA-t. The model takes account of false-positive,
false-negative, suspicious and indeterminate results.
METHODS: A Markov model was built describing the trajec-
tory and the management of patients, from the ﬁrst FNA-t and
until a conclusive diagnosis was obtained. We derived estimates
for patient, diagnostic accuracy values and follow-up from a ret-
rospective study, including patients who had their ﬁrst FNA-t in
2003 or 2004. Costs were computed from the viewpoint of the
hospital. A microcosting study was assessed to determine the unit
cost of FNA-t. Costs of hospital stays for surgery were extracted
from the hospital cost accounting. Sensitivity analyses were per-
formed. RESULTS: A total of 105/390 patients were operated.
Speciﬁcity and sensitivity values were respectively 86% and
78%. The unit cost of FNA-t was estimated to €118. Markov
modeling showed that the mean total cost of a true diagnosis
was €997 per patient, including unnecessary surgeries, FNA-t
and follow-up. Cost decreased with the capacity of the cytolo-
gist to minimize indeterminate results. CONCLUSION: The true
cost of a given procedure exceeds its unit cost of production.
This result is conditional to the performance of the cytologist
and is highly dependent on the 29% of indeterminate results.
Ultrasound-guidance would reduce this rate and the true cost by
a great deal at a relatively low unit cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in a
pediatric population. METHODS: rHGH may be administered
to pediatric patients via vial/syringe or pen injection systems pro-
vided by six manufacturers. Variation in annual drug cost is
largely a function of dosing efﬁciency and price per milligram
(mg). A budgetary impact model was developed to calculate drug
costs based on product waste and cost. Waste was calculated as
the difference between prescribed dose, based on patient weight,
and actual delivered dose, based on dosing increments and
maximum deliverable dose for pens and a ﬁxed percent waste as
derived from the literature for vials. Annual drug costs were cal-
culated based upon total mg delivered, using a daily dose of 0.03
mg/kg and wholesale acquisition cost. Total annual drug costs,
assuming equal use of vials and pens from each manufacturer,
were compared for two scenarios: 1) A mix based on national
market share and 2) restricting use to the product with lowest
waste. RESULTS: Based on the literature, waste for each vial
product was 23%, including injection error (15%) and
syringe/needle dead space (8%). Among individual pens, waste
was highest for Humatrope 24 mg (19.5%) and lowest for
Norditropin NordiFlex 5 mg (1.1%). Equal use of vials and pens
from each manufacturer resulted in the following product waste:
Tev-Tropin 23% (vial only), Nutropin 18.4%, Humatrope
14.5%, Genotropin 7.1%, Saizen 4.6%, and Norditropin 3.6%.
Restricting use to the product with least waste (Norditropin)
resulted in an 11.0% reduction in annual patient cost from
$19,196 to $17,089 compared to national share mix. CON-
CLUSION: Pen delivery systems result in less waste than vial and
syringe. Considering all approved delivery systems, Norditropin
resulted in the least product waste and lower annual patient cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in an
adult population. METHODS: rHGH may be administered to
adults via vial/syringe or pen injection systems provided by six
manufacturers. Variation in annual drug cost is largely a func-
tion of dosing efﬁciency and price per milligram (mg). A bud-
getary impact model was developed to calculate drug costs based
on product waste and cost. Waste was calculated as the differ-
ence between prescribed dose, based on patient weight, and
actual delivered dose, based on dosing increments and maximum
deliverable dose for pens and a ﬁxed percent waste as derived
from the literature for vials. Annual drug costs were calculated
based upon total mg delivered, using a daily dose of 0.016 mg/kg
and wholesale acquisition cost. Total annual drug costs, assum-
ing equal use of vials and pens from each manufacturer, were
compared for two scenarios: 1) A mix based on national market
share and 2) restricting use to the product with lowest waste.
